Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises DFDS on sale of two routes on the Irish Sea
Mandate

Vinge advises DFDS on sale of two routes on the Irish Sea

December 03, 2010

Vinge is advising DFDS in connection with the sale of two routes in the northern part of the Irish Sea to Stena Line. The sale covers the routes Belfast-Birkenhead and Belfast-Heysham, plus two ro-ro-vessels and two chartered ro-pax vessels. Stena Line will in addition take over operations at the prot terminals of Belfast, Birkenhead and Heysham. Turnover on the routes in 2009 was DKK 520m. The total consideration was EUR 47.5m. There are no conditions attached to the completion of the sale.

The Vinge team advising DFDS includes Jesper Ottergren (partner) and Anna Edström. Pär Remnelid (partner) and Johanna Bergdahl are providing competition law advice.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024